Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

GPM Reminds Investors of the October 14th Deadline in the Class Action Lawsuit Against Concordia International Corp. and Encourages Investors to Contact the Firm

GPM Reminds Investors of the October 14th Deadline in the Class Action Lawsuit Against Concordia International Corp. and Encourages Investors to Contact the Firm

Glancy Prongay & Murray LLP (“GPM”) reminds investors of the October 14, 2016 deadline to file a lead plaintiff motion in the class action lawsuit filed on behalf of investors who purchased or otherwise acquired Concordia International Corp. (“Concordia” or the “Company”) (NASDAQ: CXRX) securities between November 12, 2015, and August 12, 2016.

On August 12, 2016, Concordia issued a press release announcing that it was lowering its 2016 guidance “to reflect the impact of unexpected competition on several products in our North America segment, and current foreign currency exchange rates.” The Company also announced that Adrian de Saldanha, Concordia’s Chief Financial Officer, was leaving the Company, and that Concordia’s Board unanimously agreed to suspend the Company’s $0.075 quarterly dividend. On this news, Concordia’ stock price fell $6.33 per share, or 38%, to close at $10.03 per share on August 12, 2016, thereby injuring investors.

The complaint charges Concordia and certain of its officers with violations of the federal securities laws. Specifically, the complaint alleges that Defendants made false and/or misleading statements and/or failed to disclose: (1) that the Company was experiencing a substantial increase in market competition against the Company’s drug, Donnatal, and other products; (2) that, as a result, the Company’s financial results would suffer, and the Company would be forced to suspend its dividend; and (3) that, as a result of the foregoing, Defendants’ statements about Concordia’s business, operations, and prospects, were false and misleading and/or lacked a reasonable basis.

If you purchased or otherwise acquired Concordia shares during the Class Period, you may move the Court no later than October 14, 2016 to request appointment as lead plaintiff. To be a member of the class you need not take any action at this time; you may retain counsel of your choice or take no action and remain an absent member of the Class. If you wish to learn more about this action, or if you have any questions concerning this announcement or your rights or interests with respect to these matters, please contact Lesley Portnoy, Esquire, of GPM, 1925 Century Park East, Suite 2100, Los Angeles, California 90067 at 310-201-9150, Toll-Free at 888-773-9224, by email to shareholders@glancylaw.com, or visit our website at http://www.glancylaw.com. If you inquire by email please include your mailing address, telephone number and number of shares purchased.

This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.

Glancy Prongay & Murray LLP, Los Angeles
Lesley Portnoy, 310-201-9150 or 888-773-9224
shareholders@glancylaw.com
www.glancylaw.com



Get the latest news and updates from Stockhouse on social media

Follow STOCKHOUSE Today